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Abstract
Pharmaceutical drug development is a complex, time-consuming and expensive
process which is also limited to a relatively small number of targets. Drug
repositioning is a vital function which involves finding new uses and indications
for already approved and existing drugs. It is a cost-effective process in contrast
to experimental drug discovery. Previous studies have shown that the networkbased method is a versatile platform for drug repositioning as there exists more
biological networks which can be used to model interaction between the
biological concepts. In this thesis, we are interested in finding the best drugs for
one of the most prevailing disease, the Breast Cancer using the existing Proteinprotein interaction (PPI) networks. The proposed method is based on the idea
that if a perturbation gene expression profile inversely corelates with the disease
gene expression profile, the drug may have a curing effect on the disease. Six
samples of stroma surrounding invasive breast primary tumours and six matched
samples of normal stroma are extracted from the public functional genomics data
repository, Gene Expression Omnibus. The perturbation gene expression data
corresponding to MCF7 cell line was extracted from the National Institute of
Health’s (NIH) Library of Integrated Network-Based Cellular Signatures
(LINCS) dataset. Machine Learning techniques are used to select the best suited
drug for the breast cancer disease. We have used a ranking algorithm to obtain a
ranked list of suitable drug repurposing and repositioning candidates.
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Chapter 1
Introduction
1.1 Drug Discovery
1.1.1 What is a Drug?
In pharmacology, a drug is a chemical substance, typically of known structure,
which, when administered to a living organism, produces a biological effect [1].
A pharmaceutical drug, also called as medication or medicine, is a chemical
substance used to treat, cure, prevent, or diagnose a disease or to promote wellbeing [2].

Figure 1.1: 3D molecular structure of Ibuprofen

Figure 1.1 shows the 3D molecular structure of a drug known and sold as
Ibuprofen [3], the most common drug in the world. There are some drugs which
are not used to specifically treat disease but act as a psychoactive chemical
substance influencing a better mood by impacting the central nervous system.
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1.1.2 Traditional drug discovery pipeline
Traditional drug discovery and development procedures is highly time
consuming and comes at a high development cost. Developing a new drug takes
about 10 to 17 years and it costs between $500 billion to $2 million dollar [4].
Approximately 90% of the newly discovered drugs fail in the clinical trials due to
their side - effects or adverse effects [5] and only one in 10,000 compounds can
make it to market, and less than 20% of drugs entering Phase II clinical trials
succeed [6].

Target ID &
Selection

Candidate
Selection

IND
Filing

NDA
Filing

Basic
Research

Lead
Discovery

Preclinical
Development

Clinical
Development

Years

3

1

6

FDA
Filing
1.5

Figure 1.2: Drug Development Cycle

Figure 1.2 shows the steps involved in traditional drug discovery. Step 1 involves
basic research and target identification. Target can be defined as the pathogen in
which the drug is meant to create an effect on.

Step 2 is the Lead discovery and optimization, which is an initial stage of drug
discovery process where the small molecules (drugs) are carefully vetted to
observe traces of lead compound, a pharmacological chemical. Step 3 is the
Examining the dosage level of drugs and ensuring the safety of the drug. This
phase is essential before proceeding to clinical trials. Since a drug cannot be used
on humans without having the knowledge of whether it is safe to consume or not,
these trials are conducted on other species that have genetics resembling human
genetics. Step 4, Clinical trials are where drugs are tested on humans to study
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their effect before marketing. The final step involves getting the drug FDA
approved, where the FDA review teams thoroughly examine all the submitted
data related to the drug or device and decide to approve or not to approve it. To
minimize the time and costs associated with traditional drug discovery process
computational drug discovery is a preferred alternative.

1.1.3 Computational Drug Discovery
Computational drug discovery is an effective strategy for accelerating and
economizing drug discovery and development process [22]. It covers many
aspects of drug discovery, including computer programs for designing
compounds, tools for systematically assessing potential lead candidates and the
development of digital repositories for studying chemical interactions [23].
Because of the availability of biological macromolecule and small molecule
information, the applicability of computational drug discovery has

been

extended to most aspects of the drug discovery and development process [24],
from target identification and validation to lead discovery and optimization; the
tools can even be applied to preclinical trials, which greatly alters the pipeline for
drug discovery and development [25]. Figure 1.3 shows a flowchart for the tasks
that computational approaches have been applied to and the computational
methods used at each stage.

Figure 1.3: Computational Drug Discovery approaches
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The use of computational tools could reduce the cost of drug development by up
to 50% [26]. Drug Repurposing and Drug Repositioning is one of the remarkable
computational drug discovery methodology that is being used to overcome the
issues in the traditional drug discovery process.

1.1.4 Drug Repurposing and Drug Repositioning?
Drug Repurposing aims at finding new indications for already existing FDA
approved drugs for a disease and therefore increases the available therapeutic
choices at a fraction of cost of new drug development [7], whereas Drug
Repositioning involves finding indications for drugs that have been developed but
failed in the clinical trials or drugs that have not been approved by the FDA.
The drugs used in our research fall under one of the three categories listed below.
•

Approved

•

Experimental

•

Investigational

Approved drugs are those that have passed clinical trials. Experimental drugs are
those that have shown to bind proteins in mammals or bacteria. Investigational
drugs are at one of the phases of drug design process in one jurisdiction or more.

Drug Repurposing/Repositioning involves the same procedure but differs on the
type of drug recommended. The unapproved drugs which closely resemble the
properties of approved drugs intended to treat other disease of interest shall be
selected as suitable candidates for drug repositioning, while the approved drugs
intended to treat other disease of interest shall be selected as suitable candidates
for drug repurposing.
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1.1.5 Drug Repurposing and Drug Repositioning Methods
Figure 1.4 illustrates the different methods of Drug Repurposing. There are
different classifications for Drug Repurposing methods, each of which seeks to
categorize the existing methods depending on some important metrics.

Figure 1.4: Drug Repurposing Methods

Two major Drug Repurposing approaches are docking simulation and machine
learning. Molecular docking method try to simulate and model the physical
interactions between the drugs and targets and are used in structural molecular
biology and computer-assisted drug design [8]. Successful docking methods can
efficiently search high-dimensional conformation spaces and accurately rank the
candidate dockings using a scoring function [9]. However, there are some
limitations in the use of molecular docking in Drug Repurposing. The
requirement of known three-dimensional (3D) structure of chemical ligands and
protein targets severely limits the application of docking because the structures
of many physiologically important proteins are not fully resolved [10]. Moreover,
molecular docking methods demand significant computational resources
resulting in extended runtimes [11].
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Additionally, because of errors in the determined protein structure, and the
incomplete modeling of atomic and molecular interactions, the results of
molecular docking have high false-positive rates [10].

Machine Learning method treats Drug Repurposing as a supervised learning
problem where machine learning algorithms are applied to biological data related
to drugs and then link them to treat specific diseases. Machine learning methods
appear more favorable than docking simulation, as they can examine a larger
number of promising candidates for further experimental screening [11].
Machine learning methods can be further classified as drug-based, disease-based
or Data driven methods [10]. Drug based methods try to discover repositioning
opportunities by chemical or pharmaceutical perspective investigation, while
disease-based methods focus on disease management, symptomatology or
pathology.

If more accurate detection of pharmacological properties is needed, drug-based
methods which involve pharmacological or chemical information on drugs may
be preferred. By contrast, disease-based approaches may be preferred when there
is insufficient knowledge of drug pharmacology. Disease-based can be preferred
when the focus is on disease or therapeutic category. Each approach presents
unique informatics challenges, often requiring elements from both drug- and
disease-based methods to be incorporated for a successful process [8]. Datadriven approaches analyze large-scale ‘-omics’ data sets using statistical modeling
techniques [12].

The advances in biological sciences, have led the access to a lot of ‘-omics’
molecular data in different levels such as the genome, transcriptome, proteome
and metabolome; therefore, using data-driven approaches is an increasingly
viable option. Network modelling is one of the most used data-driven approaches.
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Networks are simple and versatile data structures on which associations can be
inferred through many statistical and computational approaches [13].
A wide variety of concepts in biology are represented in the form of Networks.
Figure 1.5 illustrates different types of biological interactions that can be
represented by networks.

Figure 1.5: Types of Biological Networks

In biological networks, nodes represent various components like genes or
proteins and edges represent the relationship between genes, proteins or the
functional similarity between genes. To identify a drug target, a network-based
strategy first reconstructs a biological network and then simulates its
interactions. The resulting interaction relationships between drug targets reveal
the potential drug targets [14]. Some of the advantages of the Network-based
method is that molecular networks can provide insights into the context in which
the drug target works and can, therefore, help understand the drug mechanisms
of action [15].
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Network algorithms can readily accomplish tasks such as visualizing various
existing interactions, adding newly discovered relationships, and superimposing
additional properties over primary components and their known interactions
[16]. Various kinds of data from different data sets could be represented in one
network. Therefore, the topological properties of the network can be used to make
predictions when biological data is missing and thus reduces the false-positive
rates [17].

1.2 Problem Statement
Given drug perturbation data and gene expression data for breast cancer, we aim
to obtain a ranked list of drugs which would make suitable candidates for drug
repurposing and drug repositioning for the breast cancer dataset. For this, six
samples of stroma surrounding invasive breast primary tumours and six matched
samples of normal stroma are extracted from the public functional genomics data
repository, Gene Expression Omnibus. The perturbation gene expression data
corresponding to MCF7 cell line was extracted from the National Institute of
Health’s (NIH) Library of Integrated Network-Based Cellular Signatures (LINCS)
dataset.

We integrate information from different sources such as molecular interaction
networks like Protein-Protein interaction networks (PPI) with the gene
expression profiles for a strong Drug Repurposing/Repositioning. We then make
use of machine learning method, the Louvain algorithm on the disease network
dataset and finally the combinatorial optimization algorithm, the Hungarian
Method is used to provide a ranked list of good drug repurposing and
repositioning candidates.
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1.3 Thesis Motivation
Researching the repurposing of unapproved drugs sharing similarities with
approved drugs for the treatment of breast cancer would help speed up the drug
design process involving phase of drug discovery and development. As a result,
years of time and billions of dollars will have been conserved to help cure breast
cancer disease. Most importantly, this thesis does its part in helping us move one
step closer to acquiring suitable drugs to tackle breast cancer.

1.4 Thesis Contribution
In this thesis, we have proposed application of existing pre-processing and
network clustering methods on the breast cancer dataset to obtain a ranked list
of suitable drug repurposing and repositioning candidates. Our novel
contribution in this thesis includes the integration of the external biological data
with the primary gene expression data in order to increase the quality of drug
repurposing or repositioning.

1.5 Thesis Organization
The rest of the thesis/ research work is organized in the following manner.
•

In Chapter 2, we discuss literature review in the area of drug repurposing
using computational approaches.

•

In Chapter 3, we introduce our proposed approach and explain all the
techniques used to obtain suitable drug repurposing candidates for the
breast cancer dataset.

•

In Chapter 4, we present the experimental results and perform an analysis
of those results.

•

Chapter 5 concludes the research by explaining insights received during
the work and setting up the field of opportunities for possible future work.
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Chapter 2
Literature Review
This chapter consists of some literature review regarding computational drug
repurposing using various disease data. Several computational approaches for
drug repurposing have been developed that is worth noting and we discuss some
of those works below.

2.1 A Network Approach for Computational Drug
Repositioning.
This paper is based on the hypothesis that a drug can be repositioned to another
drug’s curing area if two drugs share similar molecular and/or chemical
properties. The authors of this paper, Jiao Li and Zhiyong Lu [27] constructed a
disease-drug-target network based on prior knowledge (i.e., known therapeutic
uses of drugs and known drug targets). Different from the other similarity-based
methods, in drug pairwise similarity calculation, the authors have adapted a
novel bipartite-graph based method to represent the relationships between drugs
and their target proteins as a bipartite graph. Furthermore, they added the drug
structure information into the drug pairwise similarity calculation and in this way
their method boost the target similarity by making use of their corresponding
interaction information. Then, the drug pair with higher similarity score is
predicted to be repurposed to each other therapeutic area.

Limitation of this method is that the state of many structures and chemical
properties of known drug compounds are untrustworthy and many physiological
effects cannot be predicted by considering only structural features.
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2.2 A new computational drug repurposing method using established
disease-drug pair knowledge.
The paper is based on the method that if a drug-exposure gene expression profile
inversely correlates with a disease gene expression profile, the drug may have a
therapeutic effect on the disease. The authors of this paper, Draghici et al. [28] at
first formed an input matrix by combining the reversed measurements of the
genes in the disease profile and the measurements of the same genes in each of
the drug profiles. Their workflow consists of transforming the input matrix into
a lower dimensionality matrix by incorporating dimensionality reduction
technique such as principal component analysis (PCA) or Locally Linear
Embedding (LLE). Then the authors have used the known relationship between
disease and its FDA approved drugs into a transformed space using distance
metric learning algorithm. In this process, the clinically relevant drugs get close
to the disease and the Euclidean distance between disease gene expression profile
and each of the drug-exposure expression profiles is calculated. Then the drugs
are ranked based on the closest to the farthest distance from the disease.

The authors of this paper have worked towards obtaining drug repurposing
candidates for three diseases: breast cancer, rheumatoid arthritis and idiopathic
pulmonary fibrosis. They have used GEO disease data for breast cancer, CMAP
data for rheumatoid arthritis, and LINCS for idiopathic pulmonary fibrosis.

The authors of this paper have made use of only the transcriptional data, so the
results are not much reliable. Incorporating transcriptional data with available
clinical knowledge such as drug, chemical and disease biomarkers could yield
better results.
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2.3 A novel computational approach for drug repurposing using systems
biology
The authors of this paper, Draghici et al. [29] built a global network (GN) which
is the union of all KEGG human signalling pathways. Then a subgraph was
extracted from the global network comprising of the shortest paths between the
disease related genes and drug targets and termed it drug-disease network
(DDN). Then a system level analysis was applied on the gene expression
signatures of drug-disease pairs to generate gene perturbation signatures in the
drug-disease network. Further, the authors have assigned a repurposing score on
the drug disease pair and obtained a ranked drug list with potential therapeutic
effects for the given disease based on the repurposing scores. Limitation of this
paper is that the gene regulatory network constructed in the proposed method is
biased due to the existence of noise in the gene expression data.

2.4 Drug repositioning for cancer therapy based on large-scale druginduced transcriptional signatures
The authors of this paper, Lee et al. [30] have developed a series of seven
classifiers using logistic regression to predict drug repurposing candidates for the
treating of glioblastoma, lung cancer, and breast cancer.
They make use of signatures obtained from the chemical structure (S), drugtarget relation (T), and gene expression data (E). Suitable drug repurposing
candidates were predicted based on similarity of the signatures between the
compounds and disease or known its drugs.
Limitation of this method is that the method considers only Differentially
Expressed genes (DEG) in the drug dataset. DEG’s in the disease dataset are not
taken for consideration and structures for most of the drugs are not available.
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2.5 Breaking the paradigm: Dr Insight empowers signature free,
enhanced drug repurposing
The authors of this paper, Gu et al. [31] have developed a signature free, optimal
drug repurposing based on gene expression data, namely Dr. Insight which
overcomes the limitations of the existing computational frameworks. The method
considers the dysregulation of gene expression from both disease and drugperturbed data simultaneously, which renders the CEG’s as optimal features to
investigate the connections among diseases, drugs and genes. The authors have
done an extensive comparison on simulated and real cancer datasets and
validated the superior performance of Dr Insight over several popular drugrepurposing methods to detect known cancer drugs and drug–target interactions.
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Chapter 3
Proposed Methods
In this chapter, we discuss the datasets, pre-processing steps taken, and machine
learning techniques used in this thesis.

3.1 Breast Cancer
3.1.1 What is a gene?
A gene is the basic physical and functional unit of heredity. Genes are made up of
DNA and every data point generated by a DNA microarray experiment denotes
the ratio of expression levels [18]. The results from one experiment with n
number of genes on one test subject denotes a series of expression levels. In each
of these ratios, the numerator represents expression level of the gene in a varying
condition and the denominator denotes the expression level of the gene in a
reference condition. Data compiled together to form m such experiments
presents a gene expression matrix. The gene expression value will be positive if
the production of that gene is increased in that particular test case and will be
negative if the generation of that gene is decreased instead [19]. Figure 3.1 shows
a sample gene.

Figure 3.1: Gene
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3.1.2 What is Breast Cancer?
Cancer occurs as a result of mutations, or abnormal changes, in the genes
responsible for regulating the growth of cells and keeping them healthy. A
tumour can be benign - not dangerous to health or malignant - has the potential
to be dangerous. Breast cancer is a disease in which cells in the breast grow out
of control [20]. Usually breast cancer either begins in the cells of the lobules,
which are the milk-producing glands, or the ducts.

3.1.3 Why Breast Cancer?
Breast Cancer makes up 25% of all new cancer diagnoses in women across the
globe according to the American Cancer Society (ACS) [21].

It is estimated that in Canada in 2019:
•

26,900 women will be diagnosed with breast cancer. This represents 25%
of all new cancer cases in women in 2019.

•

5,000 women will die from breast cancer. This represents 13% of all
cancer deaths in women in 2019.

•

On average, 74 Canadian women will be diagnosed with breast cancer
every day and on average, 14 Canadian women will die from breast
cancer every day.
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3.2 Datasets
3.2.1 Reactive Stroma of Breast and Prostate Cancer
The disease data titled “Reactive Stroma of Breast and Prostate Cancer” was
obtained from the National Center for Biotechnology Information’s (NCBI), Gene
Expression Omnibus (GEO) portal.

GEO is a public repository that archives and freely distributes comprehensive
sets of microarray, next-generation sequencing, and other forms of highthroughput functional genomic data submitted by the scientific community. This
dataset consists of gene expression data for a large pool of breast cancer genes.
The dataset consists of stroma associated with prostate and breast invasive
tumors. It consists of 24 samples which includes, six samples of stroma
surrounding invasive breast primary tumours, six samples of stroma
surrounding invasive prostate primary tumours and six matched samples of
normal stroma for each type of tumour. Out of this we extracted the 6 samples of
breast cancer stroma and six matched samples of normal stroma related to the
breast cancer. The dataset consisted of 12 columns and 20,322 genes.

3.2.2 LINCS
The drug data was extracted from the pharmacogenomics perturbation data
which is the National Institute of Health’s (NIH) Library of Integrated NetworkBased Cellular Signatures (LINCS) dataset. This dataset consists of 21,567 drugs
in the columns and 12,328 genes in the rows. This dataset is a level 5 LINCS
dataset and consists of normalized z-score values. Level 4 LINCS data consists of
two sets of data, before administration of drugs and after administration of drugs
onto the genes in the dataset. These expression values from both the level 4
datasets are normalized to form the level 5 LINCS dataset. Figure 3.2 shows the
LINCS L1000 data processing pipeline.
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Figure 3.2: LINCS L1000 data processing

L1000 data is provided at five levels of the data processing pipeline [32]:
•

Level 1: Raw unprocessed flow cytometry data from Luminex (LXB).

•

Level 2: Gene expression values per 1000 genes after deconvolution
(GEX).

•

Level 3: Quantile-normalized gene expression profiles of landmark genes
and imputed transcripts (Q2NORM or INF).

•

Level 4: Gene signatures computed using z-scores relative to the plate
population as control (ZSPCINF) or relative to the plate vehicle control
(ZSVCINF).

•

Level 5: Differential gene expression signatures.

3.2.3 Protein-Protein Interaction Networks
Proteins are large biomolecules, or macromolecules, consisting of one or more
long chains of amino acid residues. The roles of proteins are many and varied.
Protein, DNA, RNA and other biological molecules do not work in isolation; they
cooperate with other proteins to perform a biological activity. Two molecules that
cooperate to perform a function are said to be interacting. It is the combination
of these molecules and their interactions, and not the molecules alone, that
characterize the mechanisms of a biological process. Protein–protein
17 | P a g e

interactions (PPIs) are the physical contacts of high specificity established
between two or more protein molecules as a result of biochemical events steered
by electrostatic forces including the hydrophobic effect. Protein-protein
Interactions (PPI) can be modelled as networks. Each protein is represented as a
node, and an edge between any two nodes indicates that these two proteins
interact. Figure 3.3 [37] shows an example of Protein-Protein interaction
networks, where the proteins are represented by nodes.

Figure 3.3: Protein-Protein Interaction Network

Pathway Commons is a database of biological pathways and biomolecular
interactions aggregated from many source databases. Pathway Commons has
biomolecular interaction data from Reactome, NCI Pathways, PhosphoSite,
HumanCyc,

Transfac,

MiRTarBase,

Drugbank,

Recon

X,

Comparative

Toxicogenomics Database, and KEGG [38].

In molecular biology, STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) is a biological database and web resource of known and
predicted protein–protein interactions [39]. The STRING database contains
information

from

numerous

sources,

including

experimental

data,

computational prediction methods and public text collections. The resource also
serves to highlight functional enrichments in user-provided lists of proteins,
using a number of functional classification systems such as GO, Pfam and KEGG
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[40]. The STRING database contains information on about 9.6 million proteins
from more than 2000 organisms.

3.3 Pre-processing of Datasets
The pre-processing pipeline used on the datasets to be used in the Machine
Learning methods in this thesis is explained in the following subsections.

3.3.1 Reactive Stroma of Breast Cancer Dataset
The statistical scores such as p-value, FDR-corrected p-value (or q-value) and Zscores was calculated using the sick and the healthy samples of the breast cancer
disease dataset. Having the possibility of there being a large number of false
positives is not statistically good and so we calculate the q-values using the false
discovery rate (FDR) approach.

The false discovery rate (FDR) is a method of conceptualizing the rate of type I
errors (rejection of a true null hypothesis) in null hypothesis testing when
conducting multiple comparisons. The older approaches reduced the number of
false positives while also reducing the number of true positives which is not
optimal. This newer FDR approach gives us adjusted p-values in every test case.
In simpler terms, p-value predicts that there could be 5% false positives in the
entire list of DE genes whereas q-value (FDR-adjusted p-value) predicts that
there could be 5% false positives in the significant tests.
The false discovery rate formula is [34]:
FDR = E (V/R | R > 0) P(R > 0)
Where,
•

V = Number of Type I errors (i.e. false positives)

•

R = Number of rejected hypotheses
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Q-values are the name given to the adjusted p-values found using an optimised
FDR approach. The FDR approach is optimised by using characteristics of the pvalue distribution to produce a list of q-values.
For the breast cancer dataset, the genes having FDR-corrected p-value(q-values)
< 0.05 was the Differentially Expressed genes. Out of 20,322 genes in the breast
cancer dataset, 138 genes were identified to be Differentially Expressed.

3.3.2 LINCS Drug Perturbation Data
The LINCS drug dataset consists of drugs related to 7 cell lines. Out of 7 cell lines,
we have extracted drugs belonging to the cell line “MCF7”. This way we have
multiple entries of most drugs, so we have filtered them based on the dosage and
time under administration. Within this cell line, we have filtered drugs whose
dosage was 1.11 um and whose time under administration was 24 hours.

Out of 21,567 drugs, 1844 drugs passed our criteria. Then we computed p-values
based on the z-score by using the normal distribution and FDR corrected pvalue(q-value) for each gene per drug profile to select the statistically significant
values [35].
Figure 3.4 [5] explains the LINCS pre-processing pipeline. Like the disease
dataset, the genes having FDR corrected p-value < 0.05 was considered to be
differentially expressed.

We calculated the percentage of differentially expressed genes in each drug
profile and eliminated drugs that had fewer than 1% differentially expressed
genes. So, in our dataset, out of 12,328 genes, we checked if there are more than
123 DE genes in a drug profile or not and selected only drugs that had more than
123 differentially expressed genes. This step has enabled us to select unique
instances of all drugs fitting our criteria. We have extracted a total of 110 drugs
based on these filters.
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Figure 3.4: LINCS pre-processing pipeline
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3.3.3 Protein-Protein Interaction Network Dataset
We obtained the directed protein-protein interaction network by combining
protein interactions from the “Pathway Commons Protein-Protein Interactions
database” and the “STRING” database. The PPI’s in Pathway Commons database
are classified as one of the following types in Table 3.1. We extracted the
interaction from the Pathway Commons Protein-Protein Interactions database
with the interaction types in “controls-expression-of, controls-state-change-of,
controls-phosphorylation-of and catalyses-precedes”.

Interaction Types

Description

First protein controls a reaction that
changes the state of the second protein.
First protein controls a reaction that
controls-transport-of
changes the cellular location of the second
protein.
First protein controls a reaction that
controls-phosphorylation-of changes the phosphorylation status of the
second protein.
First protein controls a conversion or a
controls-expression-of
template reaction that changes expression
of the second protein.
First protein controls a reaction whose
catalysis-precedes
output molecule is input to another
reaction controled by the second protein.
controls-state-change-of

in-complex-with
interacts-with
neighbor-of
consumption-controled-by
controls-production-of
controls-transport-ofchemical

Proteins are members of the same
complex.
Proteins are participants of the same
Molecular Interaction.
Proteins are participants or controlers of
the same interaction.
The small molecule is consumed by a
reaction that is controled by a protein
The protein controls a reaction of which
the small molecule is an output.
The protein controls a reaction that
changes cellular location of the small
molecule.

Table 3.1: Types of Protein-Protein Interaction
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Then, we extracted the directed interactions from the STRING database. The
confidence score of an interaction in STRING database is defined as the
approximate probability that a predicted link exists between two enzymes in the
same metabolic map in the KEGG database. Confidence limits are as follows
•

low confidence - 0.25 (or better),

•

medium confidence - 0.4,

•

high confidence - 0.7,

•

highest confidence - 0.9

We removed all the interaction with weak confidence, with score < 250 (i.e.,
0.25). The duplicate interactions were removed, and PPI network was formed by
combining

interactions

from

the

“Pathway

Commons

Protein-Protein

Interactions database” and “STRING” database. PPI network comprises of
904284 unique interactions.

3.4 Methodology
In this thesis, we have proposed two methodologies to find the ranked list of
drugs

which

would

make

suitable

candidates

for

Drug

Repositioning/Repurposing for the disease Breast Cancer. We formed the breast
network data from the PPI network by considering only the genes present in the
breast disease data and the disease network data consist of 716,426 unique
interactions. Then, we constructed the drug network data from the PPI network,
for each drug profile by considering only the differentially expressed genes
present in each drug profile of the drug data and obtained 110 drug networks.
Figure 3.5 represents the pipeline of our overall thesis.
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Figure 3.5: Thesis pipeline
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DRUG SUBNETWORK

In the first method, we aim to find a Differentially Expressed Subnetwork from
the disease network data. A gene is declared differentially expressed if an
observed difference or change in read counts or expression levels between two
experimental conditions is statistically significant [52]. A Differentially
Expressed subnetwork is a disease-related subnetwork of differentially expressed
interacting genes identified by an appropriate integration of a secondary network
data with the primary gene expression data. In our second method, we use
community detection algorithms to find the communities, or clusters in the
disease and the drug network data. Community detection in networks is one of
the most popular topics of modern network science. Communities or clusters are
usually groups of vertices having higher probability of being connected to each
other than to members of other groups, though other patterns are possible [44].
We will see more about these two methodologies used in this thesis later in this
chapter.

3.4.1 Hungarian Algorithm
The standard assignment problem is referred to as the problem to find a one-toone matching between tasks and agents, in order to optimize the total cost of the
assignments. The objective is either to maximize or minimize the total cost. In
this thesis we wish to find the optimal assignment of rank of drugs, by maximising
the total cost. The classical example of assignment problems is assigning jobs to
workers. Hungarian method is the most popular method which solves the
assignment problem in polynomial time. It was developed and published by
Harold Kuhn in 1955.
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The Hungarian Method is based on the principle that if a constant is added to
every element of a row and/or a column of cost matrix, the optimum solution of
the resulting assignment problem is the same as the original problem and vice
versa. The original cost matrix can be reduced to another cost matrix by adding
constants to the elements of rows and columns where the total cost or the total
completion time of an assignment is zero. Since the optimum solution remains
unchanged after this reduction, this assignment is also the optimum solution of
the original problem [48].

The Hungarian algorithm consists of the four steps:
Step 1 (Subtract row minima): In the cost-matrix, for each row, the lowest
element is subtracted from each element in that row.
Step 2 (Subtract column minima): Similarly, for each column, the lowest
element is subtracted from each element in that column.
Step 3 (Cover all zeros with a minimum number of lines): Then all the
zeros in the resulting matrix is covered using a minimum number of horizontal
and vertical lines. If n lines are required, an optimal assignment exists among the
zeros. The algorithm stops. If less than n lines are required, Step 4 is continued.
Step 4 (Create additional zeros): The smallest element (call it k) that is not
covered by a line in Step 3 is subtracted from all uncovered elements and k is
added to all elements that are covered twice.

A Walk-Through Algorithm:
We consider an example where five salesmen (1, 2, 3, 4,5) need to be assigned to
five districts (A, B, C, D, E), one salesman per district. The matrix below shows
the cost of assigning a certain worker to a certain district. The objective is to
maximize the total cost of the assignment.

Cost Matrix:
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Conversion to Minimization Problem:
The given maximization problem is converted into minimization problem by
subtracting from the highest sales value (i.e., 41) with all elements of the given
table.

Matrix Reduced Row-wise
Reduce the matrix row-wise

Step 2: Matrix Reduced Column-wise and Zeros Covered
Reduce the matrix column-wise and draw minimum number of lines to cover all
the zeros in the matrix, as shown below.
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Step 3: Add & Subtract the least Uncovered Element:
Number of lines drawn ≠ Order of matrix. Hence not optimal. Select the least
uncovered element, i.e., 4 and subtract it from other uncovered elements, add it
to the elements at intersection of line and leave the elements that are covered
with single line unchanged.

Step 4: Final Assignments
Now, number of lines drawn = Order of matrix, hence optimality is reached.

Thereby, the salesman 1 is assigned to district B, salesman 2 is assigned A,
salesman 3 is assigned to E, salesman 4 is assigned to C and salesman 5 is
assigned to district D.
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3.4.2 Differentially Expressed Subnetwork Method

Figure 3.6: Proposed Framework – DES method

In biology, a biomarker is a measurable indicator of the severity or presence of
some disease state. More generally a biomarker is anything that can be used as
an indicator of a particular disease state or some other physiological state of an
organism [41]. In the literature survey, we found that all the papers were using a
bioinformatic methods that focuses on identifying biomarkers as small subsets of
differentially expressed genes. Differentially expressed genes (DEG’s) have
limited predictive performance due to the heterogeneity within tumour samples
and across patients, moreover insufficient patient sample size and the inherent
measurement noise in microarray experiments makes the biomarkers with DEG’s
unstable [42].
Also, computational methods detecting DEG’s do not consider the dependencies
or relationships between genes in order to accurately classify the sample data,
thus identified biomarker set may contain many DEG’s with redundant
information yielding decreased prediction performance.
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So, to accurately identify effective biomarkers, new bioinformatic methods
integrating additional biological information with gene expression data have
become necessary [31].

In this thesis, we aim to identify a Differentially Expressed Subnetwork (DES) as
an effective biomarker that could help us to find the best candidate drugs for
repurposing. Figure 3.5 represents the proposed framework, which involves
finding the Differentially Expressed Subnetwork. We have obtained the
Differentially Expressed Subnetwork with the help of the Breast Network Data
and the differentially expressed genes of the disease data. The Differentially
Expressed subnetwork is obtained for each of the DEG’s in the disease data, so
138 Differentially Expressed Subnetwork is obtained. Figure 3.6 explains the
process of finding the Differentially Expressed Subnetwork.

Starting from a DEG V, the search for the Differentially Expressed Subnetwork
proceeds as follows:
•

The current aggregate N, initially contains only the differentially
Expressed gene V.

•

We iteratively aggregate its neighbour nodes U in a greedy manner using
Breadth First Search Algorithm.

•

A neighbour u is inserted into the current aggregate N if and only if its
inclusion increases the correlation between the expression of the genes in
the aggregate.

•

|"correlation (N + u) − correlation (N)" | > ∆, where ∆ is 0.001.

•

Then, the same process is repeated on the new aggregate N + u and the
process continue till the level 2 neighbours are evaluated.
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Figure 3.7: Framework for finding Differentially Expressed
Subnetwork

After obtaining the Differentially Expressed Subnetwork, the next step was to
check for the correlation of genes, between each of the Differentially Expressed
Subnetwork and the drug data. For this we have used the ABC model of Networkbased method for Drug Repositioning/Repurposing. The ABC model is based on
the idea that if a drug perturbed gene expression profile inversely correlates with
the disease gene expression profile, the drug may have a curing effect on the
disease.

Generally, suppose we know through a data source that a disease C has a certain
characteristic B i.e., disease C is caused by a downregulation of gene B and that a
compound A has some effect on B i.e., drug A restores the expression of B. Then,
we can infer that A will influence C i.e., drug A is a repositioning candidate for
disease C [43].
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Table 3.2 shows the anti-correlation labels and the correlation which makes the
drug, a suitable candidate for repurposing. Down-regulation indicates a decrease
in the production of that gene as an effect of the disease. Up-regulation indicates
an increase in the production of that particular gene as an effect of the disease.

Table 3.2: Correlation Table
For each Differentially Expressed Subnetwork(DES), a percentage score is given
based on the total number of genes that are inversely correlated between the DES
and the drug data i.e. if no genes are inversely correlated between a DES and the
drug data, then it is scored 0 and if all the genes are inversely correlated then it
is scored 100. Then finally Hungarian Algorithm is applied on the obtained score
matrix to get the ranked list of drugs which act as the potential candidate for drug
repurposing/repositioning.

3.4.3 Louvain Community Detection Method
In this thesis, in our second method we have used the community detection
algorithm on the disease network data followed by correlation analysis to find the
repurposing score and the combinatorial optimization algorithm to rank the
drugs, based on the repurposing score. We finally have a list of drugs ranked from
potentially best suited drug repurposing candidates for the disease breast cancer
to potentially less effective drug repurposing candidates.
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There are several types of algorithms used for community detection. In this thesis
we have used the Louvain community Detection Method (LDM) for detecting
communities in networks. Figure 3.7 represents the proposed framework of the
second method.

Figure 3.8: Proposed Framework – LCD Method

The Louvain method for community detection is an algorithm for detecting where
the modularity quantifies the quality of an assignment of nodes to
communities. Modularity is defined as a measure of the structure of networks or
graphs. It was designed to measure the strength of division of a network into
modules (also called groups, clusters or communities) [45]. The Louvain
clustering algorithm is illustrated in figure 3.8 [46].
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Figure 3.9:Louvain Clustering Algorithm

The algorithm is:
•

The Louvain algorithm starts from a singleton partition in which each node is
in its own community. The algorithm moves individual nodes from one
community to another to find a partition.

•

Based on the obtained partition, an aggregate network is created.

•

The algorithm then moves individual nodes in the aggregate network.

•

These steps are repeated until the quality cannot be increased further.
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The algorithm optimizes a quality function such as modularity in two elementary
phases. The first phase involves local moving of nodes and the second phase
involves the aggregation of the network. In the local moving phase, individual
nodes are moved to the community that yields the largest increase in the quality
function. In the aggregation phase, an aggregate network is created based on the
partition obtained in the local moving phase. Each community in this partition
becomes a node in the aggregate network. The two phases are repeated until the
quality function cannot be increased further [47].

We applied the Louvain community detection algorithm on the Breast Network
data and obtained 14 communities. Then the correlation analysis was performed
on each of the drug network data and the corresponding disease network
communities. In this method, we have computed two repurposing scores based
on the correlation.

Case 1:
In the first case, the score is computed based on the total number of genes that
are inversely correlated between each of Breast network communities and the
drug networks. Figure 3.9 explains the computation of the inversely corelated
gene score. In fig 3.9, Circle A consist of the disease genes and circle B consist of
the drug genes. Genes A, B, D and G are in common between the disease and the
drug genes. Among the common genes, the genes which are inversely correlated
are highlighted in red colour. These inversely correlated common genes are used
to calculate the first score.
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Figure 3.10: Gene Score calculation

Equation 3.1 shows the formula used to calculate the inversely corelated gene
score.

𝒔𝒄𝒐𝒓𝒆𝟏 =

#𝑰𝑪𝒈𝒆𝒏𝒆𝒔
|𝑵|

Where,
N – Total number of genes in common between the disease and the drug data.

𝑰𝑪𝒈𝒆𝒏𝒆𝒔 – Total number of inversely correlated genes among the common genes
between the disease and the drug data.

Case 2:
In the second case, the score is computed based on the total number of
interactions that are inversely correlated between each of Breast network
communities and the drug networks. Figure 3.10 explains the computation of the
inversely corelated edge score. In fig 3.10, Circle A consist of the interactions in
the disease network and circle B consist of the interactions in the drug network.
Interactions A
the drug network.
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B, C

D, X

Z are in common between the disease and

Initially, each interaction is scored based on the number of genes that are
inversely correlated in an interaction. Genes which are inversely correlated
among the common interactions are highlighted in red colour. If both the genes
in an interaction are inversely correlated, then the interaction is scored 2. If any
one of the genes in an interaction is inversely correlated then the interaction is
scored 1 and if no genes in an interaction is inversely correlated, then it is scored
0.

Figure 3.11: Edge Score Calculation

Equation 3.2 shows the formula used to calculate the inversely corelated edge
score.
#𝑬

𝟏
𝒔𝒆
𝒔𝒄𝒐𝒓𝒆𝟐 =
∑
#𝑬
𝟐
𝟏

37 | P a g e

Where,

𝑬 = Total number of common interactions between the disease network and the
drug network.

𝒔𝒆 = The score of each common interaction.
𝒔𝒆 = 0 if both the genes are not inversely correlated.
𝒔𝒆 = 1 if one of the genes are inversely correlated.
𝒔𝒆 = 2 if both the genes are inversely correlated.
Then the final repurposing score between each drug and disease data is computed
by taking average of the Gene score and edge score. Finally, we applied the
Hungarian algorithm to the obtained score matrix and found the list of ranked
drugs from potentially best suited drug repurposing candidates for the disease
breast cancer to potentially less effective drug repurposing candidates.
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Chapter 4
Results and Discussion
In this chapter, we shall go through the results of both the proposed methods for
the disease Breast Cancer and compare the results obtained. The results
showcase several unapproved drugs alongside approved drugs closest to the
disease indicating that the unapproved drugs share similarities with the approved
drugs which means that they are worth pursuing for repurposing.

4.1 Results
The following tables shows the ranked top 10 drugs for the disease breast cancer
obtained using our proposed methods. We selected the top 10% drugs from the
drugs lists obtained by applying the proposed methods on the breast cancer
datasets. These drugs are ranked according to the repurposing scores computed
by the systematic method from the highest to the lowest. We have used online
drug databases such as Drug Bank [49] to obtain each drugs’ FDA status. Table
4.1 shows the list of ranked drugs obtained by the DES method. The ranked list
of drugs obtained from the DES method for the disease breast cancer, comprises
of 4 approved drugs and 6 unapproved drugs. Table 4.2 shows the list of top 10
drugs obtained from our LCD method . The ranked list of drugs obtained from
our LCD method for the disease breast cancer, comprises of 8 approved drugs
and 2 unapproved drugs.
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Rank

Drugs

FDA Status

1

Pralatrexate

Approved

2

BIIB 021

Investigational

3

Idasanutlin

Investigational

4

Genz-644282

Approved

5

Inositol

Approved

6

Bardoxolone methyl

Investigational

7

sitagliptin

Approved

8

combretastatin A4

Investigational

9

AS703026

Investigational

10

CYT997

Investigational

Table 4.1: Ranked list of Drugs – DES Method

Rank

Drugs

FDA Status

1

Daunorubicin

Approved

2

Mepivacaine

Approved

3

Mitoxantrone

Approved

4

Ixazomib citrate

Approved

5

AT-7519

6

IKK2-inhibitor-V

7

R-547

8

Genz-644282

Approved

9

Sorafenib

Approved

10

L-ergothioneine

Approved

Investigational
Approved
Investigational

Table 4.2: Ranked list of Drugs – LCD Method
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4.2 Discussion
Tamoxifen, Gemcitabine, Epirubicin, Exemestane, Capecitabine, Paclitaxel,
Doxorubicin, gemcitabine, Fulvestrant, Exemestane, Neratinib, Docetaxel are
some of the FDA approved drugs for the disease breast cancer. These drugs were
included in our list of input drugs from the LINCS drug dataset to validate our
proposed methods. Table 4.3 shows the validation results for both the proposed
methods. FDA approved drugs for the disease breast cancer are highlighted in
green colour. Both our proposed methods were able to find 8 out of the 10 FDA
approved drugs for the disease breast cancer.

Rank

Method 1

Method 2

1

Gemcitabine

Capecitabine

2

Exemestane

Paclitaxel

3

Paclitaxel

Mepivacaine

4

Triptolide

Doxorubicin

5

Tamoxifen

Tofacitinib

6

Capecitabine

Fulvestrant

7

Doxorubicin

Gemcitabine

8

Neratinib

Exemestane

9

Fulvestrant

Neratinib

10

Lacidipine

Docetaxel

Table 4.3: Validation Results
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Some of our proposed drugs are already in the clinical study for the treatment of
breast cancer. For example, one of our proposed drugs by method 2, Sorafenib,
marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced
renal cell carcinoma (primary kidney cancer). A recent phase II study in 229
human epidermal growth factor receptor 2 (HER2)-negative metastatic breast
cancer patients investigated with the combination of sorafenib and capecitabine
inhibited the proliferation of breast cancer [50].

Daunorubicin, one of the proposed drugs by method 2 is an anthracycline used
in treatment of leukemia. Clinical studies proved that Human DNA TOP2A is a
marker of cell proliferation in breast cancer. Based on this evidence,
Daunorubicin which inhibits Human DNA TOP2A may have a potential
therapeutic effect on breast cancer. This hypothesis is under phase I clinical study
evaluating the effectiveness of Daunorubicin in treating breast cancer patients
(ClinicalTrials.gov identifier: NCT00004207). Mepivacaine, a local anaesthetic
that is chemically related to bupivacaine but pharmacologically related to
lidocaine. It is indicated for infiltration, nerve block, and epidural anaesthesia. In
a recent study, human breast cancer cell lines, MDA-MB-231 and MCF7, were
incubated with mepivacaine and found that the high concentration of
mepivacaine, significantly inhibited the breast cancer cell survival [51].
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Chapter 5
Conclusion and Future Work
In this thesis, we aimed to find suitable drug repurposing candidates for the
disease breast cancer using the Network-based method. We used Reactive
Stroma of Breast and Prostate cancer disease datasets, LINCS drug datasets and
the Protein-Protein interaction (PPI) networks from the “Pathway Commons
Protein-Protein Interactions database” and the “STRING” database. We
performed a series of pre-processing steps on these datasets and proposed two
different methods for achieving the drug repurposing/repositioning for the
disease breast cancer. In our first method, we have discussed methods to identify
a Differentially Expressed Subnetwork as an effective biomarker that helped us
to find the best candidate drugs for repurposing. We also discussed the ABC
model of Network based drug repurposing/repositioning.

In our second method, our proposed frameworks constructs the drug network
data and we have used the community detection algorithm on the disease
network data followed by correlation analysis on the disease communities and
the drug network data to find the repurposing score followed by the usage of
combinatorial optimization algorithm to rank the drugs, based on the
repurposing score.
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5.1 Possible Future Work
This thesis is just a small step towards Drug repurposing and Drug repositioning.
There are many directions for future research. Future work that can be conducted
includes the following: •

Our pre-processing steps and methods can be applied on a different cancer
dataset such as prostate cancer.

•

Using side-effect similarity of unapproved drugs with that of approved
drugs, drug repurposing candidates can be obtained.

These ideas can be an open problem that can be explored in the future
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